Suzhou Singmed Medical Device Science and Technology Ltd. (Singmed), a company focused on inhalation and nasal drug delivery platforms, participated in Pharmapack Europe 2026 in Paris. During the event, Singmed addressed the challenges associated with delivering large-molecule drugs, particularly issues related to controlled aerosol generation, precise droplet-size distribution, and targeted deposition within the respiratory system.
Industry discussions at Pharmapack Europe 2026 highlighted that as pharmaceutical development shifts toward more complex large-molecule therapeutics, existing inhalation and nasal delivery methods face difficulties in scaling and standardization. The main obstacle for many drug programs is not molecule discovery but the lack of reliable delivery platforms capable of consistent aerosol performance suitable for regulatory approval.
Singmed’s approach involves developing platform-based systems for inhalation and nasal drug delivery. Unlike traditional methods that focus on single products, Singmed prioritizes controlling core parameters such as aerosol generation and deposition. This strategy aims to ensure repeatable performance across various formulations and stages of development while reducing variability and risk.
The company’s next-generation soft-mist platform utilizes proprietary silicon-based atomization engineering. This technology enables controlled atomization and precise droplet-size distribution, which helps reduce inconsistencies due to device operation or formulation changes. Additionally, the design minimizes mechanical stress during aerosol generation, which is important for maintaining molecular integrity when delivering large molecules. Soft-mist generation is considered a reusable capability applicable across different products rather than being limited to individual devices.
For nasal drug delivery, Singmed uses a silicon-based Soft Mist Exhalation Delivery System (EDS) architecture. By integrating soft-mist atomization with EDS positive-pressure delivery, this system achieves targeted deposition within the nasal cavity and offers more predictable results compared to conventional spray methods. The platform also supports advanced applications such as nose-to-brain therapeutic strategies by providing scalable engineering control over the delivery process.
Singmed emphasizes rigorous in vitro performance evaluation aligned with regulatory standards from agencies like the FDA and EMA. These evaluations assess factors such as aerosol robustness, reproducibility, and consistency throughout a product’s life cycle. This structured methodology supports bioequivalence-ready development pathways and reduces uncertainty during clinical advancement.
Through its presence at Pharmapack Europe 2026, Singmed highlighted its role as a partner for companies seeking solutions to increasing molecular complexity in drug delivery. By combining silicon-based atomization with soft-mist and EDS architectures, Singmed continues to work with pharmaceutical partners to address ongoing challenges in this area.
